Novel Treatments and Technologies for Retinal Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".
Deadline for manuscript submissions: 25 July 2024 | Viewed by 649
Special Issue Editor
2. Department of Ophthalmology, Orlando College of Osteopathic Medicine, Orlando, FL 34787, USA
3. Aviceda Therapeutics, Cambridge, MA 02142, USA
Interests: age related macular degeneration; diabetic retinopathy; retinal degeneration; innate immune modulation; glyobiology; glyco-mimetic therapeutics; nanoparticles; non-viral/viral gene therapy; RNA interference; artificial intelligence; imaging biomarker; neuroprotection; clinical trials; ocular drug delivery; regenerative medicine; complement; macrophage; microglia; anti-VEGF
Special Issue Information
Dear Colleagues,
Recent advances in the pathophysiologic understanding, imaging biomarkers, artificial intelligence and clinical trial design of retinal diseases combined with technological advancements in aptamer antagonists, non-viral/viral gene-therapy, RNA interference, high affinity antibodies, receptor traps, and nanoparticle glyco-mimetics have led to several FDA-approved therapies for formerly unmet medical needs. These FDA approvals combined with the prevalence of these retinal diseases have led to an increase in the research interest in retinal diseases. The purpose of this Special Issue is to provide a snapshot of all aspects of these advancements from basic science to the identification of pathogenic molecular targets, the development of novel classes of therapeutics, the development of clinically relevant pre-clinical models, the use of artificial intelligence to determine when and how we use these novel therapeutics, and the validation of new FDA-approved endpoints. We aim for a focused yet comprehensive Special Issue.
Dr. Michael John Tolentino
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- age-related macular degeneration
- diabetic retinopathy
- retinal degeneration
- novel therapeutics
- imaging biomarkers
- artificial intelligence
- clinical trials
